Dr. Nicole Snow Calls Compounding A Permanent Bridge For Drug Access

Medical care costs climbed 5.4% since April 2024, with the CPI for medical care hitting 591.59 in March 2026 according to Bureau of Labor Statistics data. That is not a blip. That is a structural escalation. And buried inside that accelerating cost curve is a procurement shift that most hospital operators still classify as temporary. It is not.

The Signal

Compounding pharmacies are no longer the backup generator you fire up when the grid fails. They are becoming the grid. In a recent interview with Pharmaceutical Executive, Dr. Nicole Snow described compounding as a "permanent bridge" for healthcare access. Not a stopgap. Not a patch. A permanent bridge. That language matters because it signals that health systems are building long term vendor relationships with compounding pharmacies rather than treating them as episodic emergency partners.

The strategic shift underneath this is simple but enormous. Drug shortages are no longer spikes. They are the baseline operating condition of pharmaceutical supply. When your baseline assumption changes from "supply is reliable with occasional disruptions" to "supply is unreliable with occasional stability," your entire procurement architecture has to change with it. Hospital systems, specialty pharmacies, and pharma distributors are all recalibrating. The ones doing it deliberately will capture margin. The ones doing it reactively will hemorrhage cost.

That trajectory is the context for every decision below. Medical care costs are not decelerating. They are compounding. And that relentless upward pressure is precisely what makes compounding pharmacy infrastructure an economic necessity rather than a clinical curiosity. When traditional pharma procurement gets more expensive every quarter, alternatives stop being alternative.

Capital Allocation Decides Who Leads This Transition

The first decision facing hospital system operators is a classic build versus buy question. Do you invest capex in internal compounding facilities, or do you contract with external compounding pharmacies as strategic vendors? The BLS data shows medical care CPI jumped from 571.37 in January 2025 to 591.59 by March 2026. That is roughly 20 index points in fourteen months. Every one of those points represents procurement cost pressure that compounding infrastructure can partially absorb.

The framework is straightforward. If your system runs more than three facilities and manages a formulary with documented shortage exposure above 15% of line items, an internal compounding operation starts penciling out on a three to five year horizon. Below that threshold, contracted external partnerships deliver faster time to value with lower capital risk.

The decision most CFOs get wrong is modeling compounding investment against current procurement costs. That is the wrong denominator. You model it against projected procurement volatility. Traditional pharma pricing has embedded escalators, allocation constraints, and shortage premiums that are invisible until they are catastrophic. Compounding infrastructure is a hedge against that volatility. Price it like a hedge, not like a line item substitution. Health networks that evaluate this as a cost center will underinvest. Those that evaluate it as risk mitigation infrastructure will size it correctly.

Procurement Strategy Requires a Dual Source Architecture

Procurement directors at hospital systems have spent decades optimizing single source and preferred vendor relationships with major pharma distributors. That model assumed reliable supply from a concentrated manufacturing base. That assumption is broken.

The operational shift is to dual source architecture. Not as a backup plan but as a permanent procurement topology. This means qualifying compounding pharmacies through the same vendor assessment rigor you apply to traditional distributors. Quality control protocols, USP compliance verification, active pharmaceutical ingredient sourcing transparency, and liability frameworks all need to be formalized.

Here is the framework for sequencing this. Start with your top 20 shortage exposed medications. Map each one against compounding availability. For every drug where a qualified compounder can deliver equivalent product within your quality standards, establish a standing agreement with volume commitments. This is not spot buying. Spot buying compounded medications during a shortage is the most expensive and highest risk way to procure them. Standing agreements with volume floors give you pricing leverage and quality assurance.

The data supports urgency. Medical care CPI was essentially flat from July through September 2024, hovering around 564 to 566. Then it broke upward and never looked back, hitting 592.55 by February 2026. That inflection point coincides with tightening pharma supply and escalating shortage frequency. Procurement teams that built dual source strategies before that inflection absorbed the shock. Those that did not paid the premium.

Regulatory Compliance Is the Moat That Separates Winners From Liabilities

The compounding pharmacy market expanding into permanent infrastructure creates a regulatory surface area that most hospital operators are not staffed to manage. Compounding operates under a different regulatory framework than traditional pharmaceutical manufacturing. The distinction between 503A pharmacies doing patient specific compounding and 503B outsourcing facilities doing batch production matters enormously for compliance, liability, and insurance.

The decision for operations leaders is not whether to engage compounding. The market is forcing that. The decision is how to build a compliance framework that protects the organization as compounding moves from 5% of your pharmaceutical sourcing to 15% or more.

The framework here has three layers. First, vendor qualification must include FDA registration status, state board of pharmacy compliance history, and third party quality audit results. Second, internal clinical governance must establish formulary committees that specifically review and approve compounded medication protocols. Third, risk management must update liability coverage to reflect expanded compounding exposure. Most hospital system insurance policies were written when compounding was a rounding error in procurement. It is no longer a rounding error.

The cost of getting this wrong is not a fine. It is a patient safety event that destroys institutional credibility. The cost of getting it right is an operational advantage that compounds over time, because most of your competitors will not do the work.

Workforce and Talent Pipeline Will Bottleneck Before Capital Does

Every hospital system and compounding pharmacy expanding operations will hit the same constraint within 18 months. Talent. Compounding pharmacists, quality assurance specialists, and regulatory compliance professionals are a finite pool. The shift from episodic to permanent compounding infrastructure means demand for these roles is structural, not cyclical.

The decision for operations leaders is whether to build internal compounding talent or rely on external partners who have already assembled teams. The answer depends on your scale and your five year facility strategy. But regardless of your build versus buy decision on facilities, every hospital system needs at minimum one internal pharmacist with deep compounding expertise to manage vendor relationships, evaluate quality, and interface with regulators.

The framework for talent strategy mirrors the cost curve in the BLS data. Medical care CPI climbed from 570.11 in December 2024 to 591.59 in March 2026. That is a 3.8% increase in fifteen months in an already elevated category. Labor costs in specialized pharmacy roles are rising faster than that average. Early movers on talent acquisition will lock in institutional knowledge at today's rates. Late movers will pay a premium for less experienced hires because the experienced ones will already be deployed.

Start building the talent pipeline now. Partner with pharmacy schools. Create compounding rotations in your residency programs. Identify internal pharmacists with compounding interest and fund their advanced training. The organizations that treat this as a staffing exercise will struggle. The ones that treat it as a capability investment will lead.

Closing

The compounding pharmacy market did not ask permission to become permanent infrastructure. It just did. The operators who recognize this are not debating whether compounding belongs in their long term strategy. They are debating how fast to integrate it. Twelve months from now, the question will not be whether your organization has a compounding strategy. It will be whether your compounding strategy is mature enough to absorb the next supply chain shock that is already forming.

This article is part of the Industry Intelligence series on NeuralPress. New analysis published daily.